trial

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility

December 10, 2025 04:00 ET  | Source: Igyxos TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology…

3 days ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain…

4 days ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

6 days ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

December 07, 2025 16:00 ET  | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) --…

6 days ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

6 days ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

6 days ago

4D Paths Physics-Inspired QPOR Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel,…

1 week ago

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…

2 weeks ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…

3 weeks ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

November 18, 2025 16:30 ET  | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…

3 weeks ago
Show more Posts